Exelixis

We drive to deliver results and new medicines to treat and defeat cancer, giving patients hope for the future. Cancer is our cause.
__

Exelixis Business Information

Exelixis is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases. The majority of its programs focus on the discovery and development of small molecule drugs for cancer. The Company has a pipeline of compounds in various stages of development for the treatment of cancer and various metabolic, cardiovascular and inflammatory disorders. All of its development compounds were generated through its internal drug discovery activities, although it is developing certain of these compounds in collaboration with partners and has out-licensed to others. The Company is focusing its development activities on its clinical compounds, XL184, XL147 and XL765. XL184, the Company's advanced drug candidate, inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth and/or vascularization. XL147 is a selective inhibitor of PI3K while XL765 is a dual inhibitor of PI3K and mTOR.

Reviews

Overview (All Reviews)
Timeline
Insider Reviews

Who knows best how the business really performs?

Take an insider look at the business, shared by current and past employees.

Client Reviews
🎁 Ability to Deliver
🎁 Ability to Deliver
2.0
__
πŸ™Š Communication with Clients
πŸ™Š Communication with Clients
4.0
__
πŸš€ Innovation, Creativity & Technology
πŸš€ Innovation, Creativity & Technology
6.0
__
🧠 Knowledge & Skills
🧠 Knowledge & Skills
8.0
__
πŸ€‘ Value for Money
πŸ€‘ Value for Money
10
__
Company Reviews
The business doesn't yet have any Client Reviews. Did you work with Exelixis?